| 1. |
- Birgegard, Gunnar
(författare)
-
Does anything work for anaemia in myelofibrosis?
- 2014
-
Ingår i: Baillière's Best Practice & Research. - : Elsevier BV. - 1521-6926 .- 1532-1924. ; 27:2, s. 175-185
-
Tidskriftsartikel (refereegranskat)abstract
- Anaemia is a common finding at diagnosis in myelofibrosis, and becomes a symptomatic problem in most patients with time. There are several treatment options for specific anaemia treatment, none of which has been tested in large, randomized, controlled trials. However, as myelofibrosis is not a disease with spontaneous remissions, even non-randomized trials carry weight In this survey, the existing evidence will be analysed, both for the commonly used treatments like erythropoiesis-stimulating agents, androgens and thalidomide and for the new drugs in the area, and conclusions will be drawn concerning standard clinical anaemia treatment in myelofibrosis, which according to evidence from studies has a 40-50% chance of response in patients with not too advanced disease. (C) 2014 Elsevier Ltd. All rights reserved.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Quinlan, Daniel J, et al.
(författare)
-
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
- 2013
-
Ingår i: Best practice & research. Clinical haematology. - : Elsevier BV. - 1532-1924 .- 1521-6926. ; 26:2, s. 171-82
-
Tidskriftsartikel (refereegranskat)abstract
- The direct thrombin inhibitor, dabigatran, and the selective factor Xa inhibitors, rivaroxaban and apixaban, are new oral anticoagulants that are approved in many countries for prevention of venous thromboembolism in patients undergoing elective hip or knee arthroplasty. All have a rapid onset of action, a low potential for food and drug interactions and a predictable anticoagulant effect that obviates the need for routine coagulation monitoring. These agents offer a convenient alternative to conventional anticoagulant drug regimens, including parenteral low-molecular-weight heparins and fondaparinux, and oral adjusted-dose vitamin K antagonists, for the prevention of venous thromboembolism in this surgical setting. This review summarizes the pharmacology, clinical trial results, bleeding risk and practical use of these new oral anticoagulants in clinical orthopaedic practice. Potential issues to be considered when using these oral anticoagulants include renal impairment, potential drug interactions, neuraxial anaesthesia and management of bleeding.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Xochelli, Aliki, et al.
(författare)
-
Clonal B-cell lymphocytosis of marginal zone origin
- 2017
-
Ingår i: Baillière's Best Practice & Research. - : ELSEVIER SCI LTD. - 1521-6926 .- 1532-1924. ; 30:1-2, s. 77-83
-
Tidskriftsartikel (refereegranskat)abstract
- Monoclonal B cell Lymphocytosis (MBL) is the term used to characterize individuals presenting with lymphocytosis in the absence of lymphadenopathy, organomegaly or any other features suggestive of an active disease. Based on the immunophenotypic findings, MBL cases are sub-categorized into chronic lymphocytic leukemia (CLL)-like, atypical CLL and non-CLL MBL. The latter corresponds to cases with immunophenotypic features suggestive of post germinal center derivation and still represents a diagnostic conundrum. Recent studies are starting to shed light on the true biological nature and clinical significance of this entity and have led to the introduction of the novel term clonal B lymphocytosis of marginal-zone origin (CBL-MZ); as well as the acknowledgement of CBL-MZ in the latest (2016) update of the WHO classification for lymphoid malignancies. Here we provide an overview of relevant research concerning non-CLL MBL and discuss clinicobiological implications and considerations.
|
|
| 10. |
- Bremme, KA
(författare)
-
Haemostatic changes in pregnancy
- 2003
-
Ingår i: Best practice & research. Clinical haematology. - 1521-6926. ; 16:2, s. 153-168
-
Tidskriftsartikel (refereegranskat)
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
- Maclachlan, Kylee, et al.
(författare)
-
Second malignancies in multiple myeloma; emerging patterns and future directions
- 2020
-
Ingår i: Best Practice and Research: Clinical Haematology. - : Elsevier BV. - 1521-6926. ; 33:1
-
Forskningsöversikt (refereegranskat)abstract
- The changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors. This review discusses recent data refining our knowledge of these contributing factors, including current treatment modalities which increase risk (i.e. high-dose melphalan with autologous stem cell transplant and lenalidomide maintenance therapy). We highlight emerging data towards individualized risk- and response-adapted treatment strategies and discuss key areas requiring future research.
|
|
| 16. |
- Forsberg, Anna, et al.
(författare)
-
The core of after death in relation to organ donation : A grounded theory study
- 2014
-
Ingår i: Intensive & Critical Care Nursing. - : Churchill Livingstone. - 0964-3397 .- 1532-4036. ; 30:5, s. 275-282
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: The aim of this study was to investigate how intensive and critical care nurses experience and deal with after death care i.e. the period from notification of a possible braindead person, and thereby a possible organ donor, to the time of post-mortem farewell. Research methodology: Grounded theory, based on Charmaz' framework, was used to explore what characterises the ICU-nurses concerns during the process of after death and how they handle it. Data was collected from open-ended interviews. Findings: The core category: achieving a basis for organ donation through dignified and respectful care of the deceased person and the close relatives highlights the main concern of the 29informants. This concern is categorised into four main areas: safe guarding the dignity of the deceased person, respecting the relatives, dignified and respectful care, enabling a dignified farewell. Conclusion: After death care requires the provision of intense, technical, medical and nursing interventions to enable organ donation from a deceased person. It is achieved by extensive nursing efforts to preserve and safeguard the dignity of and respect for the deceased person and the close relatives, within an atmosphere of peace and tranquillity.
|
|
